Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Clarke

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Plos One|August 11, 2021
Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohortMichelle Tew, Kim Dalziel, Karin Thursky, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 30, 2024
Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation ModelsHelen A Dakin, Ni Gao, José Leal, et al.
Journal of the American Heart Association|March 24, 2021
Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial HypertensionAn Tran-Duy, Kathleen Morrisroe, Philip Clarke, et al.
Pharmacoeconomics|June 26, 2024
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor ManagementNi Gao, Helen A Dakin, Rury R Holman, et al.
Pharmacoeconomics|November 23, 2016
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic ReviewXinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, et al.
European Journal of Preventive Cardiology|July 28, 2017
Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohortXinyang Hua, Robyn McDermott, Thomas Lung, et al.
Plos Medicine|November 30, 2021
Disease-related income and economic productivity loss in New Zealand: A longitudinal analysis of linked individual-level dataTony Blakely, Finn Sigglekow, Muhammad Irfan, et al.
Lancet (London, England)|May 21, 2024
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)Amanda I Adler, Ruth L Coleman, Jose Leal, et al.
Tobacco Control|December 5, 2023
Economic effects for citizens and the government of a country-level tobacco endgame strategy: a modelling studyDriss Ait Ouakrim, Tim Wilson, Samantha Howe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 5, 2026
Health Utilities and Disutilities Associated with Complications of Type 1 Diabetes: A Systematic Review and Recommendations for Health Economic ModelsAn Tran-Duy, Ting Zhao, Liam Fernando-Canavan, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Plos One|August 11, 2021
Excess cost of care associated with sepsis in cancer patients: Results from a population-based case-control matched cohortMichelle Tew, Kim Dalziel, Karin Thursky, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 30, 2024
Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation ModelsHelen A Dakin, Ni Gao, José Leal, et al.
Journal of the American Heart Association|March 24, 2021
Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial HypertensionAn Tran-Duy, Kathleen Morrisroe, Philip Clarke, et al.
Pharmacoeconomics|June 26, 2024
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor ManagementNi Gao, Helen A Dakin, Rury R Holman, et al.
Pharmacoeconomics|November 23, 2016
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic ReviewXinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, et al.
European Journal of Preventive Cardiology|July 28, 2017
Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohortXinyang Hua, Robyn McDermott, Thomas Lung, et al.
Plos Medicine|November 30, 2021
Disease-related income and economic productivity loss in New Zealand: A longitudinal analysis of linked individual-level dataTony Blakely, Finn Sigglekow, Muhammad Irfan, et al.
Lancet (London, England)|May 21, 2024
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)Amanda I Adler, Ruth L Coleman, Jose Leal, et al.
Tobacco Control|December 5, 2023
Economic effects for citizens and the government of a country-level tobacco endgame strategy: a modelling studyDriss Ait Ouakrim, Tim Wilson, Samantha Howe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 5, 2026
Health Utilities and Disutilities Associated with Complications of Type 1 Diabetes: A Systematic Review and Recommendations for Health Economic ModelsAn Tran-Duy, Ting Zhao, Liam Fernando-Canavan, et al.
Pageof 14